Iatrogenic glaucoma therapy failure: the adverse effects of topical antiglaucoma medication treatment outcome

References

• Saadine J, Benjamin S, Pan L et al. Prevalence of visual impairment in selected eye diseases among persons aged ≥50 years with and without diabetes – United States, 2002. MMWR Morb. Mortal. Wkly Rep.53, 1069–1071 (2004).
   Google Scholar
• Quigley HA, West S, Rodriguez J et al. The prevalence of glaucoma in a population-based study in Hispanic subjects. Proyecto VER. Arch. Ophthalmol.119, 1819–1826 (2001).
   PubMed Web of Science ®Google Scholar
• Tislsch JM, Sommer A, Katz J et al. Racial variations in the prevalence of primary open-angle glaucoma. JAMA266, 369–374 (1991).
   Google Scholar
• The Eye Diseases Prevalence Research Group. Prevalence of open angle glaucoma among adults in the United States. Arch. Ophthalmol.122, 532–538 (2004).
   PubMed Web of Science ®Google Scholar
• Varma R, Paz SH, Azen SP et al.; Los Angeles Latino Eye Study Group. The Los Angeles Latino Eye Study: design, methods, and baseline data. Ophthalmology111, 1121–1131 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD et al.; for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol.120, 714–720 (2002).
   PubMed Web of Science ®Google Scholar
• Shin DH, Becker B, Kolker AE. Family history in primary open angle glaucoma. Arch. Ophthalmol.95(4), 598–600 (1977).
   PubMedGoogle Scholar
• Heijl A, Leske MC, Bengtsson B et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.12(10), 1268–1279 (2002).
   Google Scholar
• Sherwood MB, Migdal CS, Hitchings RA, Sharir M, Zimmerman TJ, Schultz JS. Initial treatment of glaucoma: surgery or medications. Surv. Ophthalmol.37, 293–305 (1993).
   PubMed Web of Science ®Google Scholar
• Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst. Rev.2, CD004399 (2004).
   Google Scholar
• Lichter PR, Musch DC, Gillespie BW et al.; CIGTS Study Group. Interim Clinical Outcomes in the Collaborative Initial Glaucoma Treatment Study (CIGTS) Comparing Initial Treatment Randomized to Medications or Surgery. Ophthalmology108, 1943–1953 (2001).
   PubMed Web of Science ®Google Scholar
• Longstaff S, Wormald RPL, Mazover A, Hitchings RA. Glaucoma triple therapy procedures: efficacy of intraocular pressure control and visual outcome. Opthalmologic. Surg.21, 786–793 (1990).
   PubMedGoogle Scholar
• Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch. Ophthal.108, 1543–1548 (1990).
   PubMed Web of Science ®Google Scholar
• Feldman RM, Gross RL, Spaeth GL et al. Risk factors for the development of Tenon’s capsule cysts after trabeculectomy. Ophthalmology96, 336–341 (1985).
   Google Scholar
• Batterbury M, Wishart PK. Is high initial aqueous outflow of benefit in trabeculectomy. Eye7, 109–112 (1993).
   Google Scholar
• Broadway DC, Grierson I, O’Brien C et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol.112, 1437–1445 (1994).
   PubMed Web of Science ®Google Scholar
• Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv. Ophthalmol.32, 149–170 (1987).
   PubMed Web of Science ®Google Scholar
• Singh J, Bell RWD, Adams A, O’Brien C. Enhancement of post-trabeculectomy bleb formation by laser suture lysis. Br. J. Ophthalmol.80, 624–627 (1996).
   Google Scholar
• Hitchings RA, Grierson I. Clinico–pathologic correlation in eyes with failed fistulizing surgery. Trans. Ophthalmol. Soc. UK103, 84–88 (1983).
   PubMedGoogle Scholar
• Young TL, Higginbotham EJ, Zou X, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology97, 1423–1427 (1990).
   PubMed Web of Science ®Google Scholar
• Broadway D, Grierson I, Hitchings RA. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br. J. Ophthalmol.77, 590–596 (1993).
   PubMed Web of Science ®Google Scholar
• Migdal C, King A. Clinical management of glaucoma. J. R. Soc. Med.93, 175–177 (2000).
   Google Scholar
• Broadway DC, Hitchings RA, Grierson I. Topical anti-glaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery. J. Glaucoma4, 136–148 (1995).
   PubMedGoogle Scholar
• Fraunfelder FW. Corneal toxicity from topical ocular and systemic medications. Cornea25(10), 1133–1138 (2006).
   PubMed Web of Science ®Google Scholar
• Nordmann JP, Auzanneau N, Ricard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual. Life Outcomes1, 75 (2003).
   PubMedGoogle Scholar
• Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol.135(5), 688–703 (2003).
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol.86(4), 418–423 (2002).
   PubMed Web of Science ®Google Scholar
• Wright P. Squamous metaplasia or epidermilization of the conjunctiva as an adverse reaction to topical medications. Trans. Ophthal. Soc. UK99, 244–246 (1979).
   PubMedGoogle Scholar
• Fechtner R, Budenz, D, Godfrey D. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Presented at: Annual Meeting of the American Glaucoma Society. Washington, DC, USA, 8 March 2008 (Poster).
   Google Scholar
• Perry H. Dry eye diagnosis and management in 2004. Curr. Opin. Ophthal.15, 299–304 (2004).
   PubMedGoogle Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma17(5), 350–355 (2008).
   PubMed Web of Science ®Google Scholar
• Perry H, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr. Opin. Ophthal.15, 299–304 (2004).
   PubMedGoogle Scholar
• Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma10, 237–249 (2001).
   PubMed Web of Science ®Google Scholar
• Vaugn DG Jr. The contamination of fluoroscein solutions with special reference to Pseudomonas aeruginosa (Bacillus pyocyaneus). Am. J. Ophthalmol.39, 55–61 (1955).
   Google Scholar
• Wilson LA. To preserve or not preserve, is that the question? Br. J. Ophthalmol.80, 583–584 (1996).
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res.32, 3–8 (2000).
   PubMed Web of Science ®Google Scholar
• Schein OD, Hibberd PL, Starch T, Baker AS, Kenyan KR. Microbial contamination of in-use ocular medications. Arch. Ophthalmol.110, 82–85 (1992).
   PubMedGoogle Scholar
• Geyer O, Bottone EJ, Podos SM, Schumer RA, Asbell PA. Microbial contamination of medications used to treat glaucoma. Br. J. Ophthalmol.79, 376–379 (1995).
   PubMed Web of Science ®Google Scholar
• Whitson JT, Varner DL, Grove D, Netland PA. Glaucoma drugs and the ocular surface. Rev. Ophthalmol.13(11), (2006).
   Google Scholar
• Grant WM, Schuman JS. Toxicology of the Eye. CC Thomas (Ed.). Springfield, IL, USA, 1990.
   Google Scholar
• Gasset AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. Am. J. Ophthalmol.78, 98–105 (1974).
   PubMed Web of Science ®Google Scholar
• Morgan JF. Problems associated with current care systems for contact lenses. Pract. Optom.1, 8 (1990).
   Google Scholar
• Brazier DJ, Hitchings RA. Atypical band keratopathy following long-term pilocarpine treatment (from Moorefields Eye Hospital). Br. J. Ophthalmol.73, 294–296 (1989).
   Google Scholar
• Atkinson WS. A colored reflex from the anterior capsule of the lens which occurs in mercurialism. Am. J. Ophthalmol.26, 685–688 (1943).
   Google Scholar
• Burn RA. Mercurialentis. Proc. R. Soc. Med. (Ophthalmological Section), 55–56, 322–326 (1962–1963).
   PubMedGoogle Scholar
• Block SS. Disinfection, Sterilization, and Preservation. Malvern PA (Ed.). Lea & Febiger, PA, USA, 1991.
   Google Scholar
• Burn RA. Mercurialentis. Proc. Royal Soc. Med.55(4), 322–326 (1962).
   PubMedGoogle Scholar
• Way WA, Matsumoto S, Apel LJ et al. Purite as a non-disruptive preservative for lubricating eye drop solutions in comparison to alternative preservatives. Investig. Ophthalmol. Vis. Sci.4, S223–B196 (2001).
   Google Scholar
• Noecker RJ, Herrygers LA, Anwarrudin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea23(5), 490–496 (2004).
   PubMed Web of Science ®Google Scholar
• Baudouin C, de Lunardo C. Short term comparative study of topical 2% cartelol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol.82, 39–42 (1998).
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphological effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology96, 327–335 (1989).
   PubMed Web of Science ®Google Scholar
• Wilson FM. Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans. Am. Ophthalmol. Soc.81, 854–865 (1983).
   PubMedGoogle Scholar
• Hirst LW, Weblin T, Novak M, Green WR, Pollack I. Drug-induced cicatrizing conjunctivitis simulating ocular pemphigoid. Cornea1, 121–128 (1982).
   Google Scholar
• Derous D, de Keizer RJW, de Wolff-Rouendaal D, Soudijn W. Conjunctival kertinisation, an abnormal reaction to an ocular β-blocker. Acta Ophthal.67, 333–338 (1989).
   Google Scholar
• Broadway DC, Grierson I, O’Brien C, Hitchings RA. The effect of topical anti-glaucoma medication on the conjunctival cell profile and the results of the trabeculectomy. Investig. Ophthalmol. Vis. Sci.34, 724 (1993).
   Google Scholar
• Brandt JD, Wittpen JR, Katz LJ, Steinmann WN, Spaeth GL. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am. J. Ophthalmol.112, 297–301 (1991).
   PubMed Web of Science ®Google Scholar
• Arici MK, Arici SD, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin. Exp. Ophthal.28, 113–117 (2000).
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effect of antiglaucoma medication: II. The outcome of filtration surgery. Arch. Ophthal.112, 1446–1454 (1994).
   PubMed Web of Science ®Google Scholar
• Quaranta CA, Russo L, Rossi Brunori P et al. Osservazioni ultrastrutturali sugli ipotetici Danni congiuntivali da farmaci β-bloccanti. Boll. Ocul.67(Suppl. 3), 345–351 (1988).
   Google Scholar
• Steuhl KP, Knorr M, Frohn A, Theil H-J. Uber den Einfluβ antiglaukomatoser Augentropfen auf die Zelldifferenzierung der Konjunktiva. Forschr. Opthalmol.88, 865–869 (1991).
   Google Scholar
• Van Buskurk EM. Adverse reactions from timolol administration. Ophthalmology87, 447–450 (1980).
   Google Scholar
• Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with antiglaucomatous medication. Ophthalmology7, 1082–1088 (1992).
   Google Scholar
• Nuzzi R, Finazzo C, Cerruti A. Adverse effect of topical antiglaucomatous medications on the conjunctiva and the lachrymal response. Int. Ophthalmol.22, 31–35 (1998).
   Web of Science ®Google Scholar
• Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv. Ther.23, 663–671 (2006).
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Fillacier K et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology106(3), 556–563 (1999).
   PubMed Web of Science ®Google Scholar
• Guenoun J-M, Baudouin C, Rat P, Pauly A, Warnet J-M, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Investig. Ophthalmol. Vis. Sci.46, 2444–2450 (2005).
   PubMed Web of Science ®Google Scholar
• Anwarrudin R, Herrygers LA, Noecker RJ. Effect of preservatives on the ocular surface in chronic glaucoma. Investig. Ophthalmol. Vis. Sci.43(Suppl.), 164 (2002) (Abstract 4008).
   Google Scholar
• Sutton A, Gilverry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluroprostaglandin receptor agonists tafluprost and latanoprost in healthy males. J. Ocul. Pharmacol. Ther.23(4), 359–365 (2007).
   PubMed Web of Science ®Google Scholar
• Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostaglandin receptor agonist: a dose–response study on pharmacodynamics and tolerability in healthy volunteers. Int. J. Pharmacol. Ther.46(8), 400–406 (2008).
   Google Scholar
• Brasnu E, Brignole-Baudouin F, Riancho L et al.In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr. Eye Res.33(4), 303–312 (2008).
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol.92, 1275–1282 (2008).
   PubMed Web of Science ®Google Scholar
• Wlliams DE, Nguyen KD, Shapourifar-Tehrani S, Kitada S, Lee DA. Effects of timolol, betaxolol, and levobunolol on human Tenon’s fibroblasts in tissue culture. Investig. Ophthalmol. Vis. Sci.33, 2233–2241 (1992).
   Google Scholar
• De Jong C, Solwijk T, Kuppens E et al. Topical timolol with and without benalkonium chloride; epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthal.232, 221–224 (1994).
   PubMed Web of Science ®Google Scholar
• Gordon J, Johnson PJ. Fibronectin Study Group – discontinuation of topical ophthalmic medications promotes healing of non-healing corneal epithelial defects. Invest. Ophthalmol. Vis. Sci.32, 1071 (1991).
   Google Scholar
• Green K, Chapman JM, Cheeks L, Clayton RM, Wilson M, Zehir A. Detergent penetration into young and adult rabbit eyes: comparative pharmacokinetics. J. Toxicol. Cut. Ocul. Toxicol.6, 89–107 (1987).
   Web of Science ®Google Scholar
• Green K, Tonjum A. The effect of benzalkonium chloride on the electropotential of the rabbit cornea. Acta Ophthalmol.53, 348–357 (1975) (Abstract).
   PubMed Web of Science ®Google Scholar